维普中文期刊产品整合服务
共被期刊论文引用了3次 您的检索式:您选中1篇文献正在查看引证文献汇总
    题名 作者 年代 出处 被引量
1替罗非班治疗缺血性卒中的研究进展显示文摘缺血性卒中是我国首位致死病因,抗血小板是基础治疗,但常用的抗血小板药物如阿司匹林、氯吡格雷并未完全覆盖所有血小板聚集的信号通路。糖蛋白(GP)Ⅱb/Ⅲa拮抗剂替罗非班作为一种新的抗血小板药物,起效快,半衰期短,具有可逆性,通过阻断血小板聚集的共同途径发挥作用。替罗非班在心血管疾病中应用成熟,但在脑血管领域仍属于探索阶段,属于超说明书用药。本文对目前的关于替罗非班治疗脑卒中的研究进行综述。郭彩霞 李晓慧 2024齐齐哈尔医学院学报2024,45,3:0
2肿瘤出芽分子机制的研究进展显示文摘肿瘤出芽是一种存在于多种实体癌中的病理现象,通常被定义为位于肿瘤侵袭前沿的孤立的一个或多达4个癌细胞的簇。肿瘤出芽的预后价值已得到了大量证据的支持,也被视为恶性肿瘤转移的关键步骤。肿瘤出芽为一个动态转化过程,本文将探究其在肿瘤细胞分离、迁移和侵袭、免疫抵抗、增殖和凋亡等具体过程中的细胞因子和分子变化,并阐明形成和维持肿瘤出芽所涉及的分子途径和基因调控通路。梁迪(综述) 刘艳荣(审校) 2024济宁医学院学报2024,47,1:0
3CSF2 upregulates CXCL3 expression in adipocytes to promote metastasis of breast cancer via the FAK signaling pathway显示文摘Recent studies have demonstrated that cancer-associated adipocytes (CAAs) in the tumor microenvironment are involved in the malignant progression of breast cancer. However, the underlying mechanism of CAA formation and its effects on the development of breast cancer are still unknown. Here, we show that CSF2 is highly expressed in both CAAs and breast cancer cells. CSF2 promotes inflammatory phenotypic changes of adipocytes through the Stat3 signaling pathway, leading to the secretion of multiple cytokines and proteases, particularly C–X–C motif chemokine ligand 3 (CXCL3). Adipocyte-derived CXCL3 binds to its specific receptor CXCR2 on breast cancer cells and activates the FAK pathway, enhancing the mesenchymal phenotype, migration, and invasion of breast cancer cells. In addition, a combination treatment targeting CSF2 and CXCR2 shows a synergistic inhibitory effect on adipocyte-induced lung metastasis of mouse 4T1 cells in vivo. These findings elucidate a novel mechanism of breast cancer metastasis and provide a potential therapeutic strategy for breast cancer metastasis.Xi He Lieliang Wang Honghui Li Yaru Liu Chang Tong Caifeng Xie Xiaohua Yan Daya Luo Xiangyang Xiong 2023Journal of Molecular Cell Biology2023,15,4:0
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费